NLS Pharma announces the acquisition of four patents including one linked to an innovative compound that NLS Pharma seeks to develop for the treatment of ADHD. Attention-Deficit/Hyperactivity Disorder (ADHD) is considered by OECD as one of the most frequently monitored developmental syndromes worldw more
To use all functions of this page, please activate cookies in your browser.